Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics / Photoacoustic and Ultrasonic Imaging · Journal article
Acs Applied Bio Materials · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical in vitro investigation of a biodegradable nanoparticle co-loaded with an imaging agent (indocyanine green J-aggregates) and paclitaxel, designed for photoacoustic-guided chemotherapy of triple-negative breast cancer. The work demonstrates proof-of-concept in cultured TNBC cells but lacks animal data, pharmacokinetic evidence, or clinical translation necessary to support efficacy claims.
In vitro cell-based proof-of-concept study. Triple-negative breast cancer cells (cell line not further specified in abstract). Intervention: PTX-ICGJ-Ps-aEGFR: biodegradable polymersomes co-encapsulating indocyanine green J-aggregates and paclitaxel, targeted to human epidermal growth factor receptors. Compared with: Free paclitaxel drug.
PTX-ICGJ-Ps achieve 10% w/w paclitaxel loading with pH-dependent sustained release PTX-ICGJ-Ps-aEGFR exhibit prolonged and target-specific cytotoxic effect on TNBC cells after 30 min treatment, reported as significantly higher than free drug Nanoparticles composed of FDA-approved materials and measure sub-100 nm in size
No in vivo pharmacokinetics, biodistribution, or animal efficacy data reported No quantitative comparison of cytotoxicity reported (e.g., IC50, fold-change, p-value, or confidence interval)
This work is at a preclinical discovery stage and does not yet provide evidence suitable for clinical decision-making. Substantial in vivo validation and pharmacokinetic characterization would be required before considering clinical translation.
Early-stage in vitro work demonstrating proof-of-concept for a nanotheranostic platform in cell models; no animal or clinical data reported, and efficacy claims are based on cultured TNBC cells without in vivo validation or comparative clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This work is at a preclinical discovery stage and does not yet provide evidence suitable for clinical decision-making. Substantial in vivo validation and pharmacokinetic characterization would be required before considering clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Treatment of solid tumors remains one of the biggest challenges in oncology. Targeted nanotherapeutics could significantly improve treatment efficacy and reduce side effects. However, their efficient implementation requires knowledge of pharmacokinetics (PK) and biodistribution (BD) during therapy administration that would allow dose optimization for personalized treatment. To address this need, we developed a nanotheranostic platform that combines photoacoustic imaging (PAI) with near-infrared contrast agents (i.e., indocyanine green J-aggregates, ICGJ) and anticancer drugs (i.e., paclitaxel, PTX) co-encapsulated in biodegradable and pH-sensitive sub-100 nm polymersomes (PTX-ICGJ-Ps) that are composed of all FDA-approved materials. The thick hydrophobic membrane of ICGJ-Ps not only provides protection of the imaging agent, ICGJ, but also facilitates high loading of PTX (10% w/w), and pH-dependent sustained release of the drug. PTX-ICGJ-Ps targeted to human epidermal growth factor receptors (PTX-ICGJ-Ps-aEGFR) exhibit a prolonged and target-specific cytotoxic effect on triple-negative breast cancer (TNBC) cells after just 30 min of treatment, which is significantly higher than the treatment with the free drug. Furthermore, the interaction of PTX-ICGJ-Ps-aEGFR with TNBC cells can be monitored by PAI with high specificity and sensitivity. These data indicate that PTX-ICGJ-Ps-aEGFR meet many of the key attributes of a clinically translatable platform for development of image-guided, personalized therapy of TNBC and other tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.